NASDAQ
MoonLake Immunotherapeutics (MLTX) has a free cash flow growth of -12.74% as of Friday, May 29, 2026. This represents a 45.67% decrease compared to its 12-month average of -8.75%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.